Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Multiple Myeloma 4Lymphoma 4Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Hereditary Sensory and Autonomic Neuropathies 2Hematologic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1

Interventions

Doxorubicin 25Gemcitabine 16Trabectedin 12Ifosfamide 12Radiotherapy 11Docetaxel 10Dacarbazine 8pazopanib 7Nivolumab 6Specimen Handling 5liposomal doxorubicin 4Temozolomide 4Biopsy 4pembrolizumab 3Sunitinib 3Sorafenib 3Radiation 3Magnetic Resonance Spectroscopy 3Filgrastim 3rucaparib 2pegfilgrastim 2olaratumab 2eribulin 2durvalumab 2cixutumumab 2cemiplimab 2brostallicin 2belinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leiomyosarcoma × sapanisertib × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡